• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

High-throughput Blood Antigen Array Genotyping for Blood Donors

September 1, 2020

Alloimmunization to red blood cell (RBC), human leukocyte (HLA), and human platelet (HPA) antigens can lead to hemolytic transfusion reactions and lower increments.  Researchers with the Blood Transfusion Genomics Consortium have developed a high-throughput, genome-wide blood donor antigen typing system to analyze 48 RBC, HLA, and HPA antigens with 9,180 coding variants for approximately $40 per sample (including equipment, labor, and analysis).  Using this array-based system, Applied Biosystems UK Biobank version 2 Axiom Array (UKBBv2 array), and the previously published bloodTyper algorithm, antigen typing data was generated for 7,984 blood donors from Europe, Asia and Africa.  These donors had already been typed by the National Health Service Blood and Transplant and Sanquin and by serological phenotyping systems.  Array genotyping results were 99.91%, 99.97%, and 99.03% concordant with the serological phenotyping results for RBCs, HPA, and HLA, respectively, increasing the number of matching donors for complex patients with multiple alloantibodies 2.6-fold.  Further validation of the array is required, particularly in non-European populations, but the system could dramatically improve options for transfusion recipients.

Reference:

Gleadall NS, Veldhuisen B, Gollub J, Butterworth AS, et al, on behalf of the Blood Transfusion Genomics Consortium.  Development and validation of a universal blood donor genotyping platform:  a multinational prospective study.  Blood Advances 2020; 4(15); 3495-3506.   

 

Filed Under

  • News
  • Serology/Genotyping

Recommended

  • Transfusion Testing Strategies for Multiple Myeloma Patients Undergoing Anti-CD38 Therapy

  • Antigen Density on Surface of RBCs a Factor in RBC Clearance in Incompatible Transfusions

  • AABB Clinical Practice Guidelines for RBC Transfusions

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • 2024 Serious Hazards of Transfusions (SHOT) Report in the U.K.

  • Machine Learning Model for Estimating Perioperative Transfusion Risks

  • Blood Transfusion Strategies for Major Trauma

  • Storage Duration Affects Hematological and Metabolic Parameters in Patients with Sickle Cell Disease

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley